Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

- New Progression-Free Survival, Disease Control and Neurotoxicity Data To Be Presented at 2009 ASCO Annual Meeting Continue to Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for First-Line Treatment of Colorectal Cancer -

- Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st -

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The new data demonstrated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, and oxaliplatin, given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen, have similar anti-tumor activity in the treatment of first-line metastatic CRC, as assessed by progression-free survival (PFS) and disease control measured by tumor response rate. New data derived by three independent assessments of neurotoxicity indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in FOLPI compared with oxaliplatin in FOLFOX (p<0.0019).

"Oxaliplatin given as part of the FOLFOX-based regimen is the current standard of care for metastatic colorectal cancer, but is associated with severe neuropathy at increasing cumulative doses approaching 800 mg/meter squared. This significant side effect may cause patients extreme pain, numbness and weakness, which is often long-lasting and, in many cases, requires patients to discontinue treatment," said Richard Goldberg, M.D., associate director of clinical research for the University of North Car
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , ... REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) ... organizations to launch Cholesterol Counts , an awareness ... cholesterol, their numbers, and the risks associated with high ... www. CholesterolCounts .com to take a brief ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... has decided to enter rehab in order to get rid of ... ,Calum, who was recently snapped in a sleazy romp with two ... ,"Im a bad boy. I go out and ... debauched things with the wrong women. Ive been sowing my oats ...
... But the man who set off the panic is ... in the disease. The man himself has been identified as ... coughing, has no fever and does not appear to be ... staff at the National Jewish Medical and Research Center will ...
... to double current funding levels for the President's Emergency ... five years after the program's original mandate expires next ... authorized $15 billion over five years for HIV/AIDS and ... to the Global Fund To Fight AIDS, Tuberculosis and ...
... Technologies, Inc. (NTI) announced today the presentation of new ... and updates on the clinical development of their ... ischaemic stroke at the 16th annual European Stroke Congress ... a defibrinogenating agent derived from the venom of the ...
... announced today that the U.S. Food and Drug ... (NDA) of its marketing partner, Critical Therapeutics, ... CR(TM) offers twice-daily, extended-release dosing. Under a co-promotion ... 2007, DEY will co-market Critical Therapeutics' ZYFLO CR(TM). ...
... Month, and to commemorate the occasion 27 walks will ... to Cure Scleroderma walks all share a common purpose: ... ,"These events galvanize our patient communities while raising the ... disease," said Frances Waldron, chief executive officer of the ...
Cached Medicine News:Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... Special Low-profile Hourglass Jaw Design ... Through A Minimal Incision.,Mirror Polished Blades ... Acting Handle Mechanism Offers Control Over ... Prevent The Lens From Tilting During ...
... Opening Is Designed To Pinch And ... A Separate Cystotome. The 11mm Jaws Are Formed,To ... Incision.,The Distal Jaws Have Platforms, And The Proximal ... Pick Up Of Iris. The Unique Jaw Structures ...
2.5V Halogen source, fiber-optic delivery, 3X magnification, pocket-sized....
... offer patented Sensomatic® handles that ... up and switch off when ... of light from 2.5V halogen ... of examination area. Used ...
Medicine Products: